PathNet adds PTEN and FGFR3 biomarker testing in-house
PathNet said August 25, 2026, that it will begin offering PTEN and FGFR3 biomarker stains in-house for prostate and bladder cancer testing. The move expands the lab’s urologic pathology menu and is aimed at helping clinicians make treatment decisions with more tumor-specific data.
Why it matters: - PTEN and FGFR3 staining can help pathologists and clinicians better characterize prostate and bladder cancers. - Bringing the assays in-house can shorten the testing workflow and keep more of the process inside PathNet’s laboratory. - The addition broadens PathNet’s urologic pathology offering at a time when biomarker-driven treatment decisions are becoming more important.
What happened: - PathNet announced it will offer PTEN and FGFR3 biomarker stains in-house in its laboratory. - The announcement was made Aug. 25, 2026, from Little Rock, Arkansas. - PTEN and FGFR3 testing will be added to PathNet’s immunohistochemistry, or IHC, menu.
The details: - PTEN measures PTEN protein loss in prostate cancer tumors. - PTEN loss is associated with tumor aggressiveness. - FGFR3 measures the presence of the FGFR3 protein in bladder cancer cases. - FGFR3 is a driver of alteration in papillary urothelial carcinoma. - The FGFR3 stain is used to help differentiate low-grade from high-grade papillary urothelial carcinoma. - PTEN can be ordered conditionally based on clinician criteria or ordered individually for a case. - PathNet said adding PTEN and FGFR3 expands its existing urologic pathology offerings.
Between the lines: - PathNet is positioning biomarker testing as part of a broader push toward data-supported cancer care. - CEO Jason Camilletti said adding biomarkers like PTEN and FGFR3 helps clinicians make treatment decisions based on a patient’s individual cancer progression. - Camilletti also said moving the tests in-house will help PathNet serve clients better and improve patient care.
What's next: - PathNet will begin processing the PTEN and FGFR3 stains internally as part of its laboratory workflow. - The company is directing customers to its website for more information at PathNet’s website.
The bottom line: - PathNet is expanding its urologic pathology capabilities with two biomarkers that can sharpen cancer classification and support treatment planning.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Little Rock Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.